Daniel Waterkamp

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.7K citations · Full text

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +12

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +9

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Jeffrey J. Wallin, Johanna C. Bendell, Roel Funke et al. · Nature Communications · 2016 · 690 citations · Full text

Tumor Biology, Tumor Immunology, Cancer Immunosurveillance +14

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

David Cunningham, István Láng, Eugenio Marcuello et al. · The Lancet Oncology · 2013 · 642 citations

Elderly Patients, Gastrointestinal Oncology, Medicine +10

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

Thomas Gruenberger, John Bridgewater, Ian Chau et al. · Annals of Oncology · 2014 · 347 citations

Hepatology, Phase Ii Trial, Medicine +6